Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 27;9(2):20552173231169463. doi: 10.1177/20552173231169463

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Absolute (unadjusted) percentage of patients with sNfL levels ≥16 pg/mL for each treatment group over time. Comparisons were adjusted for age, sex, the presence of gadolinium-enhancing lesions, Expanded Disability Status Scale score, baseline sNfL level, and actual body mass index. GA: glatiramer acetate; IFN: interferon; IM: intramuscular; sNfL: serum neurofilament light-chain. *p < 0.05 for change from baseline; **p < 0.001 for change from baseline; ***p < 0.0001 for change from baseline.